Vasoocclusion in sickle cell anemia: Are platelets really involved?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 7, 2006, Pages 1415-1416

  Bennett, Joel S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 914 BRB II/III ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; CD40 LIGAND; CYTOKINE; HYDROXYUREA; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; THROMBOCYTE FACTOR 4; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CYTOKINE RELEASE; DOSE RESPONSE; EDITORIAL; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; VASCULAR ENDOTHELIUM; BLOOD; METABOLISM; NOTE; VASCULAR DISEASE;

ANEMIA, SICKLE CELL; BLOOD PLATELETS; CD40 LIGAND; HUMANS; VASCULAR DISEASES;

EID: 33745954426     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000227595.97898.3f     Document Type: Editorial

References (11)

1. Hebbel RP, Yamada O, Moldow CF, Jacob HA, White JG. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium. J Clin Invest. 1980;65:154-160.
2. 1 and glycoprotein IV (CD36) are expressed on reticulocytes in sickle cell anemia. Blood. 1993;82:3548-3555.
3. v-family integrins through novel integrin binding mechanisms. Blood. 2001;98:458-466.
4. 1 integrin activation and adhesion in sickle reticulocytes. J Biol Chem. 2004;279:42393-42402.
5. Zennadi R, Hines PC, De Castro LM, Cartron J-P, Parise LV, Telen MJ. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-αvβ3 interactions. Blood. 2004;104:3774-3781.
6. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risks and benefits up to 9 years of treatment. J Am Med Assoc. 2003;289:1645-1651.
7. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F. Platelet activation in patients with sickle cell disease. Br J Haematol. 1998;100:741-749.
8. Lee SP, Ataga KI, Orringer EP, Phillips DR, Parise LV. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1626-1631.
9. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
10. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction on endothelial cells. Nature 1998;391:591-594.
11. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749-1754.